Home・Aktien・Omeros Corp

Omeros Corp

Geschlossen

BrancheGesundheitswesen

12.95 3.27

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.85

Max

12.58

Schlüsselkennzahlen
By Trading Economics
Einkommen	-35M 51M
Verkäufe	9.9M 9.9M
KGV Branchendurchschnitt	9.947 64.641
EPS	0.57
Gewinnspanne	518.033
Angestellte	175
EBITDA	86M 57M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+162.74% upside

Dividenden
By Acuity
Nächstes Ergebnis	13. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-216M 821M
Vorheriger Eröffnungskurs	9.68
Vorheriger Schlusskurs	12.95

Nachrichtenstimmung

By Acuity

84%

16%

314 / 340 Ranking in Healthcare

Omeros Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Omeros Corp Prognose

Kursziel

By TipRanks

162.74% Vorteil

12-Monats-Prognose

Durchschnitt 33 USD 162.74%

Hoch 33 USD

Tief 33 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Omeros Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Omeros Corp – Dist abgegeben haben.

Stimmung

By Acuity

314 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.